Phenytoin alters Purkinje cell axon morphology and targeting in vitro.
In adult mice, administration of the anticonvulsive drug phenytoin caused focal swellings along the Purkinje cell axon correlated with ataxia and incoordination of movements. In our model, we used murine cerebellar slice cultures to study the influence of phenytoin on postnatal Purkinje cell axon differentiation. Almost all of our untreated cultures developed to mature-like cerebellar tissue. Immunohistochemistry with anti-calbindin-D28k or UCHTI (anti-CD3) antibodies revealed numerous Purkinje cell axons in the white matter. In the area of the deep cerebellar nuclei, immunolabelled axons formed a large axonal plexus. The few neurofilament-positive neurons in this area were densely covered with Purkinje cell axon terminals. The synaptophysin immunoreactivity revealed connections between the terminals and the neurons of the deep cerebellar nuclei. Treatment of cerebellar slice cultures with phenytoin (10-80 microM) for 10-16 days resulted in focal swellings of different size along the axon. The number of swellings increased with an increasing dosage. At concentrations of 40 microM phenytoin, Purkinje cell axons seemed to be unable to invade the deep cerebellar nuclei, but numerous aberrant, recurrent collaterals could be detected immunohistochemically with the two specific Purkinje cell antibodies. Possible cytotoxic effects after treatment, such as dendritic degeneration and a decrease in the number of immunolabelled Purkinje cells, were observed above 40 microM phenytoin. These data suggest that the response of juvenile Purkinje cells is dependent upon the dosage of the antiepileptic drug because of morphological alterations as well as a misrouting of previously established connections.
Tauer
U
U
Department of Neuropathology, University of Freiburg, Germany.
Knoth
R
R
Volk
B
B
D000328:Adult; D000818:Animals; D000927:Anticonvulsants / Q000494:pharmacology* / Q000633:toxicity; D001369:Axons / Q000737:chemistry / Q000187:drug effects* / Q000648:ultrastructure; D017252:CD3 Complex / Q000032:analysis; D064092:Calbindin 1; D064026:Calbindins; D002454:Cell Differentiation / Q000187:drug effects; D002531:Cerebellum / Q000166:cytology / Q000187:drug effects* / Q000254:growth & development; D004305:Dose-Response Relationship, Drug; D006801:Humans; D051379:Mice; D008810:Mice, Inbred C57BL; D018613:Microscopy, Confocal; D009419:Nerve Tissue Proteins / Q000032:analysis; D010672:Phenytoin / Q000494:pharmacology* / Q000633:toxicity; D011689:Purkinje Cells / Q000737:chemistry / Q000187:drug effects* / Q000648:ultrastructure; D064030:S100 Calcium Binding Protein G / Q000032:analysis; D016708:Synaptophysin / Q000032:analysis
D000927:Anticonvulsants; C576498:CALB1 protein, human; D017252:CD3 Complex; C576499:Calb1 protein, mouse; D064092:Calbindin 1; D064026:Calbindins; D009419:Nerve Tissue Proteins; D064030:S100 Calcium Binding Protein G; D016708:Synaptophysin; D010672:Phenytoin